Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer

Urology

Volumn 69, Issue 1 SUPPL., 2007, Pages 62-79

  Sternberg, Cora N ^a   Donat, S Machele ^b   Bellmunt, Joaquim ^c   Millikan, Randall E ^d   Stadler, Walter ^e   De Mulder, Pieter ^f   Sherif, Amir ^g   von der Maase, Hans ^h   Tsukamoto, Taiji ⁱ   Soloway, Mark S ^j  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ SAPPORO MEDICAL UNIVERSITY   (Japan)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINBLASTINE; VINFLUNINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYSTECTOMY; DRUG MEGADOSE; HUMAN; INTERMETHOD COMPARISON; METASTASIS; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER;

EID: 33846581566     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.11.018     Document Type: Note

References (147)

1. Abrams P, Grant A, and Khoury S. Evidence-based medicine: overview of the main steps for developing and grading guideline recommendations. In Abrams P, Cardozo L, Khoury S, et al (Eds), Incontinence, Volume 1. Plymouth, United Kingdom, Health Publications Ltd., pp 10-11.
2. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
3. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: a contemporary series. J Urol 165 (2001) 1111-1116
4. Bassi P., Ferrante G.D., Piazza N., et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161 (1999) 1494-1497
5. Ghoneim M.A., el-Mekresh M.M., el-Baz M.A., et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 158 (1997) 393-399
6. Sternberg C.N. Current perspectives in muscle invasive bladder cancer. Eur J Cancer 38 (2002) 460-467
7. Sternberg C.N., Pansadoro V., Calabrò F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 97 (2003) 1644-1652
8. Herr H.W., and Scher H.I. Surgery of invasive bladder cancer: is pathologic staging necessary?. Semin Oncol 17 (1990) 590-597
9. Sanchez-Ortiz R.F., Huang W.C., Mick R., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115
10. Stein J.P. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol 169 (2003) 116-117
11. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354 (1999) 533-540
12. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866 published correction appears in N Engl J Med 2003;349:1880
13. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19 (2001) 4005-4013
14. Hall M.C., Swanson D.A., and Dinney C.P. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology 47 (1996) 826-830
15. Bassi P., Pagano F., Pappagallo G., et al. Neoadjuvant M-VAC of invasive bladder cancer: the G.U.O.N.E. multicenter phase III trial. Eur Urol 33 suppl 1 (1998) 142
16. Sherif A., Rintala E., Mestad O., et al., Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer: Nordic cystectomy trial 2. Scand J Urol Nephrol 36 (2002) 419-425
17. Wallace D.M., Raghavan D., Kelly K.A., et al. Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67 (1991) 608-615
18. Coppin C.M., Gospodarowicz M.K., James K., et al., National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14 (1996) 2901-2907
19. Martinez P.J.A., Gonzalez M.M., Arocena F., et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153 pt 2 (1995) 964-973
20. Natale R.B., Grossman H.B., Blumenstein B., et al. SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant M-VAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. [abstract]. Proceedings of the American Society of Clinical Oncology 20 (1995) 2a
21. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother 8 suppl 4 (1996) 345-346
22. Orsatti M., Curotto A., and Canobbio L. Altering chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 33 (1995) 173-178
23. Abol-Enein H., El M.M., El B.M., et al. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomized study. Br J Urol 80 suppl 2 (1997) 49
24. Malmstrom P.U., Rintala E., Wahlqvist R., et al. Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 155 (1996) 1903-1906
25. Hall R.R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Annu Meet Am Soc Clin Oncol 21 (2002) 178a
26. Sherif A., Rintala E., Mestad O., et al. Neoadjuvant platinum based combination chemotherapy improves overall survival in patients with locally advanced bladder cancer: a meta-analysis of two Nordic collaborative studies of 620 patients. J Urol 169 (2003) 307
27. Sternberg C.N., and Parmar M.K.B. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle invasive bladder cancer. J Clin Oncol 19 suppl 1 (2001) 21S-26S
28. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361 (2003) 1927-1934
29. Winquist E., Kirchner T.S., Segal R., et al. Genitourinary Cancer Disease Site Group of Cancer Care Ontario Program in Evidence-Based Care Practise Guidelines Initiative: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171 (2004) 561-569
30. Herr H.W., Faulkner J.R., Grossman H.B., et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22 (2004) 2781-2789
31. Hautmann R.E. Urinary diversion: ileal conduit to neobladder. J Urol 169 (2003) 834-842
32. Ritchie J.P., Skinner D.G., and Kaufman J.J. Radical cystectomy for carcinoma of the bladder: 16 years of experience. J Urol 113 (1975) 186-189
33. Bredael J.J., Croker B.P., and Glenn J.F. The curability of invasive bladder cancer treated by radical cystectomy. Eur Urol 6 (1980) 206-210
34. Mathur V.K., Krahn H.P., and Ramsey E.W. Total cystectomy for bladder cancer. J Urol 125 (1981) 784-786
35. Skinner D.G., and Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in the management of invasive bladder cancer. J Urol 131 (1984) 1069-1072
36. Montie J.E., Straffon R.A., and Stewart B.H. Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol 131 (1984) 477-482
37. Giuliani L., Gilberti C., and Martorrama G. Results of radical cystectomy for primary bladder cancer. Urology 26 (1985) 243-245
38. Roehrborn C.G., Sagalowsky A.I., and Peters P.C. Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146 (1991) 36-39
39. Pagano F., Bassi P., Galetti T.P., et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145 (1991) 45-50
40. Wishnow K.I., and Tenney D.M. Will Rogers and the results of radical cystectomy for invasive bladder cancer. Urol Clin North Am 18 (1991) 529-537
41. Waehre H., Ous S., Klevmark B., et al. A bladder cancer multi-institutional experience with total cystectomy for muscle invasive bladder cancer. Cancer 72 (1993) 3044-3051
42. Vieweg J., Gschwend J.E., Herr H.W., et al. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 161 (1999) 72-76
43. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogenous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
44. Frazier H.A., Robertson J.E., Dodge R.K., et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 71 (1993) 3993-4001
45. Amling C.L., Thrasher J.B., Frazier H.A., et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151 (1994) 31-35
46. Stein J.P. Indications for early cystectomy. Semin Urol Oncol 18 (2000) 289-295
47. Flocks R.H. Treatment of patients with carcinoma of the bladder. JAMA 145 (1951) 295-301
48. Milner W.A. The role of conservative surgery in the treatment of bladder tumors. Br J Urol 26 (1954) 375-386
49. Barnes R.W., Bergman R.T., Hadley H.L., et al. Control of bladder tumors by endoscopic surgery. J Urol 97 (1967) 864-868
50. O'Flynn J.D., Smith J.D., and Hanson J.S. Transurethral resection for the assessment and treatment of vesical neoplasms: a review of 800 consecutive cases. Eur Urol 1 (1975) 38-40
51. Barnes R.W., Dick A.L., Hadley H.L., et al. Survival following transurethral resection of bladder carcinoma. Cancer Res 37 (1977) 2895-2898
52. Herr H.W. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 138 (1987) 1162-1163
53. Henry K., Miller J., Mari M., et al. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140 (1988) 964-967
54. Solsona E., Iborra I., Ricos J.V., et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 159 (1998) 95-99
55. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19 (2001) 89-93
56. Herr H.W. Uncertainty, stage, and outcome of invasive bladder cancer. J Urol 152 pt 1 (1994) 401-402
57. Hall R.R., Newling D.W., Ramsden P.D., et al. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 56 (1984) 668-672
58. Herr H.W., Bajorin D.F., and Scher H.I. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16 (1998) 1298-1301
59. Thomas D.J., Roberts J.T., Hall R.R., et al. Radical transurethral resection and chemotherapy in the treatment of muscle invasive bladder cancer: a long-term follow-up. Br J Urol 83 (1999) 432-437
60. Angulo J.C., Sanchez-Chapado M., Lopez J.I., et al. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J Urol 155 (1996) 1897-1902
61. Sternberg C.N., Pansadoro V., Calabrò F., et al. Neoadjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 10 (1999) 1301-1305
62. De la Rosa F., Garcia-Carbonero R., Passas J., et al. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study. J Urol 167 (2002) 2413-2418
63. Srougi M., and Simon S.D. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5 year follow-up. J Urol 151 (1994) 593-597
64. Shipley W.U., Kaufman D.S., Tester W.J., et al., Radiation Therapy Oncology Group. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97 suppl 8 (2003) 2115-2119
65. Sauer R., Birkenhake S., Kühn R., et al. Muscle-invasive bladder cancer: transurethral resection and radiochemotherapy as an organ-sparing treatment option. In: Petrovich Z., Baert L., and Brady L.W. (Eds). Carcinoma of the Bladder (1998), Springer, New York 205-214
66. Housset M., Dufour B., Maulard-Durdux C., et al. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. [abstract]. Proc Am Soc Clin Oncol 16 (1997) 319A
67. Tester W., Porter A., and Asbell S. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25 (1993) 783-790
68. Tester W., Caplan R., and Heaney J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14 (1996) 119-126
69. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16 (1998) 3576-3583
70. Sauer R., and Rodel C. Biological selection for organ conservation. Eur J Cancer 37 suppl 6 (2001) S286
71. Durdux C., Housset M., and Dufour B. Altered fractionation in chemo-radiation for bladder cancer. Eur J Cancer 37 suppl 6 (2001) S286
72. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60 (2002) 62-67
73. Sternberg C.N. Neoadjuvant and adjuvant chemotherapy of bladder cancer: is there a role?. Ann Oncol 13 suppl 4 (2002) 273-279
74. de Braud F., Maffezzini M., Vitale V., et al. Bladder cancer. Crit Rev Oncol Hematol 41 (2002) 89-106
75. Skinner D.G., Daniels J.R., Russell C.A., et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145 (1991) 459-467
76. Stockle M., Meyenburg W., Wellek S., et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148 (1992) 302-307
77. Studer U.E., Bacchi M., Biedermann C., et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152 (1994) 81-84
78. Bono A.V., Benvenuti C., Gibba A., et al. Adjuvant chemotherapy in locally advanced bladder cancer: final analysis of a controlled multicentre study. Acta Urol Ital 11 (1997) 5-8
79. Freiha F., Reese J., and Torti F.M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155 (1996) 495-499 discussion 499-500
80. Otto T., Börgemann C., Krege S., et al. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2,M0)-a phase III study. Eur Urol 39 suppl 5 (2001) 147
81. Logothetis C.J., Johnson D.E., Chong C., et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6 (1988) 1590-1596
82. Stockle M., Meyenburg W., and Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long term results of a controlled prospective study and further clinical experience. J Urol 153 (1995) 47-52
83. Sylvester R., and Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11 (2000) 851-856
84. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
85. Sternberg C.N., de Mulder P.H.M., Schornagel J.H., et al., European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
86. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
87. Loehrer P., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
88. Logothetis C.J., Dexeus F., Finn L., et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
89. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) in advanced urothelial tumors. J Urol 133 (1985) 403-407
90. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 117 (1999) 3173-3181
91. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546
92. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
93. Geller N.L., Sternberg C.N., Penenberg D., et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67 (1991) 1525-1531
94. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95 (2002) 751-757
95. Hillcoat B.L., Raghavan D., Matthews J., et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7 (1989) 706-709
96. Stoter G., Splinter T.A., Child J.A., et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137 (1987) 663-667
97. Harker W., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. J Clin Oncol 3 (1985) 1463-1470
98. Mead G.M., Russell M., Clark P., et al., MRC Advanced Bladder Cancer Working Party. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. Br J Cancer 78 (1998) 1067-1075
99. Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 29 suppl 3 (2002) 40-45
100. Calabrò F., and Sternberg C.N. High-risk metastatic urothelial cancer: chances for cure?. Curr Opin Urol 12 (2002) 441-448
101. Calabrò F., and Sternberg C.N. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 20 (2002) 158-166
102. Sternberg C.N. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Curr Opin Urol 11 (2001) 523-529
103. Hussain M., Vaishampayan U., and Smith D.C. Novel gemcitabine-containing triplets in the management of urothelial cancer. Semin Oncol 29 suppl 3 (2002) 20-24
104. Bamias A., Aravantinos G., and Deliveliotis C. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. [published correction appears in J Clin Oncol 2004;22:1771]. J Clin Oncol 22 (2004) 220-228
105. Sternberg C.N. Gemcitabine in bladder cancer. Semin Oncol 27 (2000) 31-39
106. Sengelov L., Kamby C., and von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 39 (2001) 634-642
107. Juffs H.G., Moore M.J., and Tannock I.F. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 3 (2002) 738-747
108. Bellmunt J., Albanell J., Gallego O.S., et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70 (1992) 1974-1979
109. Waxman J., and Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 suppl C (1993) 21-25
110. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 3 (2003) 11-19
111. Misset J.L. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol 29 suppl 3 (2002) 36-39
112. Sternberg C.N., and Vogelzang N.J. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 46 suppl (2003) S105-S115
113. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
114. von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10 (1999) 1461-1465
115. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000) 1921-1927
116. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Trials Group. J Clin Oncol 17 (1999) 2876-2881
117. Stadler W.M., Hayden A., von der Maase H., et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7 (2002) 153-157
118. Roth B.J., Dreicer R., and Einhorn L.H. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264-2270
119. Dreicer R., Gustin D.M., See W.A., et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156 (1996) 1606-1608
120. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer (1996) Proceedings of the American Society of Clinical Oncology; May 18-21; Philadelphia, PA. Abstract 617.
121. Dreicer R., Manola J., Roth B.J., et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18 (2000) 1058-1061
122. Burch P.A., Richardson R.L., Cha S.S., et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma. J Urol 164 (2000) 1538-1542
123. McCaffrey J.A., Hilton S., Mazumdar M., et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15 (1997) 1853-1857
124. de Wit R., Kruit W.H., Stoter G., et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer. Results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78 (1998) 1342-1345
125. Sengelov L., Kamby C., Lund B., et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16 (1998) 3392-3397
126. Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative. Ann Oncol 10 (1999) 1385-1388
127. Garcia del Muro X., Marcuello E., Guma J., et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86 (2002) 326-330
128. Sternberg C.N., and Calabrò F. The management of bladder cancer in the elderly. Tumori 88 suppl 1 (2002) S128-S129
129. Bellmunt J., de Wit R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit"' patients with advanced bladder cancer. Eur J Cancer 37 (2001) 2212-2215
130. Stadler W.M. Gemcitabine doublets in advanced urothelial cancer. Semin Oncol 29 suppl 3 (2002) 15-19
131. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18 (2000) 2537-2544
132. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regiment. J Clin Oncol 16 (1998) 255-260
133. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16 (1998) 1844-1848
134. Boccardo F., Pace M., Guarneri D., et al. Carboplatin, methotrexate and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer 73 (1994) 1932-1936
135. Bellmunt J., Pace A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80 (1997) 1966-1972
136. Petrioli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic cancer patients: a randomized phase II study. Cancer 77 (1996) 344-351
137. Sternberg C.N., Calabrò F., Pizzocaro G., et al. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998
138. Meluch A.A., Greco F.A., Burris III H.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19 (2001) 3018-3024
139. Parameswaran R., Fisch M.J., Ansari R.H., et al. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 20 (2001) 200a
140. Guardino A.E., and Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 21 (2002) 150b
141. Fechner G.H., Siener R., Reimann M., et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. [abstract]. J Urol 167 suppl (2002) 284
142. Kaufmann D.S., Carducci M.A., Kuzel T., et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 21 (2002) 192a
143. Manola J.B., Dreicer R., and Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: report of a phase II Eastern Cooperative Oncology Group trial. [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 21 (2002) 200a
144. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18 (2000) 3247-3255
145. Bellmunt J., de Wit R., Albiol S., et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 47 (2003) 195-206
146. Hussain M., Vaishampayan U., Du W., et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
147. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671-1678